XING Technologies



XING has proprietary diagnostic nanotechnology platforms which promise to:  

    1. dramatically reduce the costs for screening of disease,
    2. enable early and accurate diagnosis as well as monitoring of disease, and
    3. provide precision in guiding therapy

The application of this technology is global, detecting genetic markers in applications such as:

    1. agriculture
    2. aquaculture
    3. veterinary science
    4. human health and wellness

The 3 key technologies addressed by XING Technologies are:

Single-Drop Genomics (‘Laboratory in a Drop’)


  • Single-Drop Genomics (SDG) enables the rapid, accurate, cost effective diagnostics with the potential for point-of-care nucleic acid (DNA, meRNA, RNA) detection of disease in humans, animals and plant life

Existing detection:

  • Currently detection is time-consuming and involves expensive laboratory processes

Detection using SDG:

  • Utilizes nanotechnology to perform a comprehensive analysis of nucleic acid within a single drop (urine, blood, saliva, biopsy)
  • Involves laboratory equipment requiring a lower level of technical expertise and training
  • Provides an accurate measurement within 35 minutes
  • Potential to be sensitive to a single DNA molecule
  • Can perform multiple tests at once
  • Adaptable to all pathogens (fungi, bacterial, viruses) and cancer

Single Drop Proteomics or SDP


  • Single Drop Proteomics allows the analysis of the proteome quickly and efficiently
  • Proteins are the core machinery of living cells that are:
    • corrupted during disease; or
    • introduced by pathogens
  • 60% of the diagnostic market utilises protein capture

Existing detection:

  • Proteins are typically detected by capture agents such as antibodies
  • Antibody capture technology is 45 years old
  • Production of antibodies (polyclonal and monoclonal antibodies) use a range of technologies, including cell culture and inoculation of animals including mice and rabbits.
  • Antibodies need to be screened for specificity and avidity, to identify the most appropriate molecules
  • Antibodies are not very temperature stable, requiring refrigeration
  • Antibody detection generally requires laboratory facilities; although point-of-care technologies are available for selected targets

Detection using Single Drop Proteomics

  • SDP is a novel  protein capture reagent
  • Employs yeast to produce reagents and does not require the use of animals in production
  • Economic and efficient to produce
  • Programmable for any protein antigen (infectious disease or cancer neo-antigen)
  • Temperature, freeze and surface stable
  • Enables point-of-care, label-free protein detection and cell capture

Circulating Tumour Cell Capture


  • Circulating Tumour Cells (CTCs) are cells shed from a primary tumour that disseminate in the body’s circulatory system. These cells constitute ‘seeds’ for the subsequent growth of metastases (secondary tumours) in vital distant organs. The vast majority of cancer-related deaths occur through metastatic spread
  • CTCs are present in very small numbers and less than 0.01% of CTCs typically form metastases
  • Detection and observation of CTC levels in the bloodstream can provide an early signal  diagnostic of metastases
  • CTCs can assist in assessing the prognosis and likely disease progression
  • Monitoring of CTC levels can provide valuable feedback on the efficacy of drug treatments

Existing practice and current technology:

  • The majority of metastases are currently detected by imaging techniques, at which point a tumour is advanced with limited treatment options
  • Isolation and characterisation of CTCs in the blood stream has represented a major technological challenge
  • Current CTC detection methods largely utilise either biological separation or physical separation

Biological separation using antigen-antibody bindings (PSA test for prostate cancer indication is an example of molecular based antigen-antibody binding)

Physical separation techniques usually employ a screen filter to isolate cells for culture growth or direct characterization

Following detection and enumeration CTC cells need to be characterized to provide details of the changes in CTC biology

Existing practices are slow, cumbersome, expensive and for this reason not currently widely available in clinical practice

Detection and monitoring using CTC Capture

  • CTC Capture provides rapid and effective monitoring of CTC cells utilising a unique and patented CTC detection chip
  • Detection involves direct and accurate measurement of CTC cell populations
  • Detection is quick with the potential to be applied in the laboratory or as a point-of-care assay
  • Economical
  • Monitoring can be personalised to a patient’s specific disease – only the relevant CTC subpopulations are monitored
  • Technology enables continual and frequent monitoring, increasing the probability of detecting early changes and response to treatment can be observed
  • Empowers the doctor and patient
  • More recently this technology has been expanded to include capture and characterisation of immune cells

Use of technology

Each of the above 3 technologies can be used independently to enable significantly improved detection, treatment and monitoring of disease

The use of the technologies in combination will provide even greater accuracy and certainty, as the three different biological indications of disease are cross-correlated and utilised to identify and monitor disease progression and response to treatment provided at extremely low levels in the organism.